| 000 | 01006 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250516025525.0 | ||
| 264 | 0 | _c20110503 | |
| 008 | 201105s 0 0 eng d | ||
| 022 | _a1756-1833 | ||
| 024 | 7 |
_a10.1136/bmj.d1126 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMackin, Paul | |
| 245 | 0 | 0 |
_aAtypical antipsychotic drugs. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cMar 2011 |
||
| 300 |
_ad1126 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntipsychotic Agents _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aParanoid Disorders _xdrug therapy |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aSchizophrenia _xdrug therapy |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aThomas, Simon H L | |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 342 _gp. d1126 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.d1126 _zAvailable from publisher's website |
| 999 |
_c20650827 _d20650827 |
||